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Teichoic acids: synthesis and applications
Daan van der Es, Wouter F. J. Hogendorf, Herman S. Overkleeft,
Gijsbert A. van der Marel and Jeroen D. C. Code´e*
This review describes the developments in the synthesis of teichoic acids (TA) – glycosylated
poly(alditolphosphates) – and the application of these fragments in immunological studies. These structurally
diverse biopolymers are omnipresent constituents of the Gram-positive bacterial cell wall where they fulfill a
variety of vital functions. They have been and continue to be attractive synthetic targets because of their
challenging structures and the fact that their microheterogeneity precludes their isolation in single and pure
enough form from natural sources. Progress in glycosylation chemistry and the development of effective
phosphorylation chemistry has driven TA synthesis over the years, and highly complex and large TA
structures can now reliably be targeted. Starting from the first TA synthesis in 1981, this review highlights the
progress made in the field over the years. The synthesized TA fragments have been used to unravel their
role in immunology and it is described how focused libraries of TAs have been used to discover the active
principles of the TA polymers that interact with the innate immune system. Recently, synthetic TA fragments
have also found applications as well-defined synthetic antigens for the generation of novel vaccine
modalities to combat Gram-positive bacterial infections. It is foreseen that synthetic TA fragments will be
valuable tools in the future to unravel the mode of action of these biomolecules at the molecular level. They
will be instrumental in discovering and characterizing their designated biological binding partners, be it
pattern recognition receptors or carbohydrate binding lectins or biomachinery enzymes. This review thus
serves to showcase the potential of organic synthesis for (chemical) biology and immunology.
Introduction
Teichoic acids (TAs) are structurally diverse anionic glyco-
polymers and prime constituents of the Gram-positive bacterial
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cell wall (teichoic is derived from the ancient Greek stem
teiw- meaning wall-related). These phosphodiester-based bio-
molecules include the membrane anchored lipoteichoic acid
(LTA) and the peptidoglycan-bound wall teichoic acid (WTA). They
perform crucial functions in the cell envelope (see Fig. 1) as they
provide control over the rigidity and porosity of the cell wall and
influence the bacterium’s morphology.1–4 They are engaged in cell-
division, cation homeostasis and protection against antimicrobial
peptides and antibiotics. LTAs are involved in biofilm formation5
and binding of bacteriophages.6 Recently, WTAs have been shown
to mask bacterial epitopes (including LTA-based epitopes) for
binding of antibodies.7 Gram-positive bacteria lacking TAs can only
be cultured under very specific circumstances, indicating the vital
function of these structurally diverse biopolymers.8
As TAs are abundant in the Gram-positive bacterial cell-wall,
they represent obvious targets for the immune system. It has
been speculated that LTA is the Gram-positive equivalent to the
Gram-negative lipopolysaccharide (LPS), a very powerful innate
immune system stimulating agent responsible for the induction
of septic shock during infections with Gram-negative bacteria.
However, there has been much debate on the role of TAs in the
immune response. Initial studies were hampered by diﬃculties
encountered in TA isolation and purification. Both partially
degraded and impure preparations9–11 were used providing a
cloudy image of the immunological effect of these components.
Improved purification protocols for LTA (mild butanol extraction
as opposed to the previously employed hot phenol extraction
methods) have delivered pure LTA preparations that have been
shown to be capable of inducing a bona fide innate immune
response.12 This review provides an overview of the synthetic
chemistry that has been devised to generate well-defined
TA-fragments. In doing so, it illustrates the development in
organic synthesis approaches and strategies to provide both
structurally complex and structurally diverse TAs. Applications
of the synthesized TAs in the elucidation of their involvement in
innate immune activation, and their role as antigens in novel
vaccine modalities is described. The reported studies clearly
show that structural variation in the TA molecules has a profound
effect on their interaction with the immune system.
TA structures
The two main classes of TAs, LTAs and WTAs, can each be
divided in sub-categories. Fischer13–15 introduced the first
classification of LTAs and he defined four distinct LTA classes
(Fig. 2A). Type I encompasses linear glycerol phosphate repeats,
that can be decorated with alanine or carbohydrate residues.
Type II and III LTA’s consist of galactosylated glycerol phosphate
repeats where the carbohydrate residue is part of the polymer
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chain. The repeating unit of type II LTA is a digalactosyl glycerol
phosphate and type III is built up from monogalactosyl glycerol
phosphates. Notably, both are encountered in only one bacterial
species.16 The LTA from Streptococcus pneumonia has been desig-
nated as type IV LTA and with the detection of more diverse LTA
structures, other classes have been introduced.4 For example, the
LTA isolated from Clostridium difficile,17 was designated as type V
LTA. This TA features a backbone that is not connected through
the polyol moiety, but instead features a phosphodiester linkage
between two C-6 hydroxyl functionalities.
The WTAs can also be divided in diﬀerent classes. Based on
their work on the genus Nocardiopsis, Stackebrandt et al.18,19
suggested four classes for the structure and linkage of the
repeating units (Fig. 2B). Similar to Fischer’s LTA class I,
WTA type I includes all polyol phosphates (glycerol phosphate,
ribitol phosphate, etc.) linked from polyol to polyol via a
phosphodiester linkage. In the backbone of type II WTAs a
carbohydrate residue is incorporated, with the polyol con-
nected to the anomeric center of carbohydrate residue through
an acetal linkage. Type III and IV are copolymers of glycosyl-1-
phosphates and type I repeating units (type III) or of type I and
type II repeating units (type IV). The isolation of even more
complicated copolymers will eventually necessitate the defini-
tion of more types, but no such TAs have hitherto been isolated.
Besides these diﬀerent types of TAs, bacteria can also produce
exo-polysaccharides, some of which feature alditol residues and
phosphodiesters, making classification of these biopolymers
an even more diﬃcult task.
Fig. 1 Examples of teichoic acids in the Gram-positive bacterial cell wall.
Fig. 2 Teichoic acid classes as proposed by Fischer (A) and Stackebrandt (B).
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Biosynthesis of TAs
The biosynthesis of LTA19,20 and WTA21 diﬀers significantly,
taking place in diﬀerent cell locations and using diﬀerent
building blocks. Type I LTAs are generally synthesized on the
glycolipid anchor, on the outside of the cell membrane,
by transferring the glycerol phosphate building block from
phosphatidylglycerol (PG) onto the nascent TA chain.22 In
S. aureus, the synthesis is initiated by the glycosyltransferase
YpfP that generates the glycolipid anchor (Fig. 3A). This anchor
is synthesized on the inside of the lipid membrane and flipped
to the outside by LtaA. The construction of the poly-glycerol
phosphate chain is executed by LTA synthase (LtaS),23 a
membrane bound polymerase featuring five transmembrane
domains and an extracellular catalytic domain. LtaS transfers
the glycerol phosphate from phosphatidyl glycerol (PG, Fig. 3B)
by action of an active-site threonine residue that first covalently
captures the glycerol phosphate moiety of PG thereby releasing
diacylglycerol. Next, the glycerol phosphate moiety is trans-
ferred to the growing TA chain. D-Alanylation of LTA fragments
is carried out by an ensemble of enzymes, DltA, B, C and D.19
This membrane bound multi-enzyme system first binds alanine
from the cytoplasmic space and transfers it to the outside of the
cell. There the load is delivered to the actual transferase, which
attaches the alanine residue to the membrane anchored LTA.
It is postulated that glycosylation of teichoic acids proceeds
in a similar manner, but the enzymes involved have yet to be
characterized.
Type IV LTA biosynthesis24 diﬀers significantly from type I
LTA synthesis. The proposed type IV LTA biosynthesis pathway
involves cytoplasmic assembly of the complex repeating unit
on an undecaprenyl carrier. After phosphocholination of the
monomeric repeating unit the building blocks are oligomerized
on the cytoplasmic side of the cell membrane. Finally the
complete dolichol-TA structure is transported over the membrane
and the oligomer is transferred onto the lipid anchor to finish the
LTA synthesis. Interestingly, the oligomer can also be transferred
to the peptidoglycan to yield S. pneumonia WTA. The enzymes
involved in the biosynthesis of types II, III and V LTA are currently
unknown, but it is likely that the mechanism is more similar to
WTA than type I LTA biosynthesis.
Most work on WTA biosynthesis has concentrated on type I
WTAs, in particular B. subtilis poly-glycerol or ribitol phosphate
WTA and S. aureus poly(ribitol phosphate).21 The common
linkage unit that connects the poly(alditol phosphate) chain
to the peptidoglycan is a b-N-acetyl-mannosamine-(1,4)-a-N-
acetyl-glucosamine-1-phosphate disaccharide that is linked
through a phosphodiester linkage to a muramic acid moiety
in the peptidoglycan.2 The synthesis of this linker is performed
on an undecaprenyl phosphate carrier by the consecutive action
of TarO and TarA (or TagO and TagA for glycerol teichoic acids).
Next, a glycerol phosphate residue is transferred to the linker
disaccharide by TarB (or TagB) using cytidine diphosphate
glycerol (CDP-glycerol) as the glycerol phosphate donor (see
Fig. 3B). This sets the stage for the assembly of the poly(glycerol
phosphate) by TagF or the poly(ribitol phosphate) by TarK
Fig. 3 (A) Biosynthetic pathways of LTA and WTA in Staphylococcus aureus. (B) Structures of phosphatidylglycerol (containing sn-glycerol-1-phosphate)
and CDP-glycerol (containing sn-glycerol-3-phosphate).
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and L in B. subtilis. Of note, the stereochemistry of the glycerol
phosphate that is transferred during WTA synthesis (sn-glycerol-3-
phosphate, for sn-numbering see Fig. 3B) diﬀers from the
stereochemistry of the glycerol phosphate building blocks in
LTA synthesis (sn-glycerol-1-phosphate). For the assembly of
poly(ribitol phosphate) WTA chain in S. aureus first another
glycerol phosphate moiety is attached by TarF, after which TarL
generates the ribitol phosphate polymer using CDP-ribitol as a
substrate. Finally the poly(glycerol phosphate) and poly(ribitol
phosphate) WTA chain are decorated with carbohydrate
residues by various enzymes (TarM and TarS in S. aureus25).
The complete polymer is subsequently transported through the
membrane by a membrane-bound hetero tetrameric complex
consisting of TarG and TarH and transferred from the undecaprenyl
support to the peptidoglycan. The mechanism for this last step is
not clear at present, but it is thought that the set of enzymes TarTUV
is involved. Interestingly, the transfer of D-alanine residues is
executed at this final stage of WTA synthesis. This mechanism is
unclear as well but it has been proposed that the DltABCD system
involved in LTA-alanylation is responsible and that D-alaninemay be
transferred from LTA to WTA.19
Chemical synthesis of TAs
The microheterogeneity and polymeric nature of TAs make it
impossible to isolate fragments of these biopolymers having
a single substitution pattern and well-defined length. Organic
synthesis can generate well-defined fragments with predeter-
mined substituents.26 Non-natural and more stable analogues
can be generated to probe the eﬀect of substituents at the
molecular level and synthetically accessed material is devoid of
biological impurities that can thwart (immunological) evaluation
of the material. Finally, organic synthesis can provide TA frag-
ments equipped with appropriate conjugation handles that can be
exploited in the generation of semi-synthetic vaccine modalities
and analytic tools, such as TA-microarrays.
Synthetic interest in TAs started in the early 1980’s and
the first chemical synthesis of a teichoic acid fragment was
reported by Van Boeckel et al. in 1981, who described the
assembly of a Bacillus atrophaeus (formerly known as B. subtilis
var. niger) trimer repeat.27 As depicted in Scheme 1, they coupled
phosphodiester 2 and primary alcohol 1 using 1-(2,4,6-
triisopropylbenzenesulfonyl)-3-nitro-1H-1,2,4-triazole (TPSNT)
as condensing agent to construct the phosphotriester linkage.
The phosphate on the primary alcohol was masked as an
aniline phosphoramidate. The resulting dimer was treated with
isopentyl nitrite to remove the aniline and liberate the phos-
phodiester of 3, that could be elongated in a second coupling
cycle to give protected timer 5. Deprotection of the oligomer
was achieved by first unmasking the tribromoethyl groups,
using zinc, followed by removal of the ortho-chlorophenyl
group. Removal of the acetyl esters, followed by cleavage of
the THP-acetal under acidic conditions yielded deprotected 6,
in 73% yield28 from 5.
Continuing their eﬀorts towards the assembly of well-defined
TA fragments, the Van Boom group synthesized a fragment of
S. aureus LTA, composed of three glycerol phosphate residues
coupled to a gentiobiose based glycolipid anchor.29 Van Boom
and co-workers were also the first to report on automated solid
phase synthesis of a TA-fragment. Using state-of-the-art phosphor-
amidite chemistry as introduced by Beaucage,30 Westerduin et al.
assembled a pentameric Bacillus licheniformis WTA-fragment as
depicted in Scheme 2.31 Using an automated DNA/RNA synthesizer,
the fragment was assembled employing coupling cycles that
entailed: (i) removal of the DMT group (2% trichloroacetic acid in
DCM); (ii) phosphoramidite coupling using building block 8 under
the agency of tetrazole in MeCN; (iii) capping of the unreacted
alcohols (Ac2O, 2,6-lutidine and N-methylimidazole); (iv) oxidation
Scheme 1 van Boeckel’s Bacillus atrophaeus TA-synthesis. Reagents and conditions: (a) TPSNT, pyridine, 56%; (b) isopentyl nitrite, pyridine/AcOH, 80%;
(c) TPSNT, pyridine, 79%; (d) (i) Zn, pTSOH, pyridine, 88%, (ii) tetramethylguanidinium-4-nitrobenzaldoximate, THF, (iii) aq. NH3, 87% over 2 steps, (iv) 0.1 M
HCl, dioxane/H2O, 96%.
Chem Soc Rev Review Article
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
9 
D
ec
em
be
r 2
01
6.
 D
ow
nl
oa
de
d 
on
 1
5/
02
/2
01
7 
12
:0
9:
09
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
Chem. Soc. Rev. This journal is©The Royal Society of Chemistry 2016
of the formed phosphite triesters using I2 in 2,6-lutidine and
1,4-dioxane. Three repetitions of this coupling cycle delivered
the resin-bound target compound. Upon ammonia treatment of
the resin, the product was cleaved from the resin and the base
labile protecting groups (the acetyl esters and the cyanoethyl
phosphotriesters) removed. The target compound was purified
by size exclusion chromatography to provide, after global
deprotection by hydrogenolysis, pentamer 12 in 29% from
immobilized 10. At the time 50 equivalents of phosphoramidite
8 were required to push the reaction to completion but the
synthesis was accomplished in a time in which the chemistry
and automated synthesis methodology were only just conceived.
Recent syntheses (vide infra) require a significantly smaller amount
of building block, but build on exactly the same chemistry.
Surprisingly, it wasn’t until the recent syntheses reported by
Hogendorf et al. that more TA fragments were synthesized
using this eﬀective synthesis technique.
In 1992 the Kusumoto group published the synthesis of
the proposed structure of Streptococcus pyogenes LTA.32 Using
phosphoramidite chemistry they synthesized tetramer 18 using
a block coupling strategy (Scheme 3). To this end, dimeric
phosphotriester 15 was generated from glycerol nucleophile 13
and phosphoramidite 14. Selective TBS removal followed by
phosphoramidite introduction then yielded 16, where selective
PMB removal from 15 yielded alcohol 17. These two diglycerol
phosphates were condensed to give a tetramer repeat, of which
the primary alcohol was liberated by TBS removal and subse-
quently transformed into a phosphoramidite moiety to give
tetramer 18. Coupling of this fragment to kojibiose glycolipid
19 yielded protected LTA fragment 20, which was deprotected
in a single hydrogenation event to yield 21. Two years later,
the same glycerol phosphate oligomer was coupled to the
glycolipid anchor from E. hirae, bearing an additional lipid tail.33
Both fragments were evaluated for their innate immune-
stimulating potential but no activity was established.34
In 2003, after almost a decade of silence in TA-synthesis,
Schmidt and co-workers reported on the synthesis of a
Staphylococcus aureus LTA fragment.35 Notably, this group
succeeded in the generation of fragments having diﬀerent
substituents on the glycerol phosphate backbone, including
the labile alanine esters (Scheme 4). The disaccharide glycero-
lipid anchor was made from gentiobiose and was equipped
with a phosphoramidite to yield 26. Glycerol phosphoramidites
23 and 24 were synthesized from commercial solketal and
either equipped with an N-acetylglucosamine or a PMB group
on the 2-OH. A TBDPS-ether was selected to serve as temporary
protecting group for the primary alcohol to be elongated during
the synthesis. Starting from di-O-benzyl glycerol 22 six coupling
and desilylation steps yielded hexamer glycerol phosphate 25.
The coupling between hexamer glycerol phosphate 25 and lipid
anchor phosphoramidite 26 proceeded uneventfully and sub-
sequent PMB cleavage set the stage for the introduction of
the alanine residues. Both D- and L-alanine residues were
incorporated to investigate how the stereochemistry at the
aC-atom aﬀects the activity of the TA fragment. The alanine
residues were introduced using Cbz-protected alanine in con-
junction with a PyBOP, NMI condensation cocktail. Global
deprotection of the LTA fragment was achieved using hydro-
genolysis over Pearlman’s catalyst (Pd(OH)2) in a mixture
of DCM/MeOH/H2O to solubilize the amphiphilic molecule.
Target compounds 28 and 29, featuring four D-alanine or four
L-alanine esters were obtained in 22% and 17%, respectively.
Immunological evaluation of the compounds,36–38 alongside
isolated LTA (using the optimized mild n-butanol extraction
procedure) and TAs lacking the lipid anchor as well as the
lipid anchor alone revealed that the synthetic material with the
Scheme 2 First automated solid phase synthesis of an TA-fragment by Westerduin et al. Reagents and conditions: (a) 2-cyanoethyl
N,N-diisopropylchlorophosphoramidite, DIPEA, DCM, 98%; (b) succinic anhydride, pyridine, DMAP, 45 1C, 90%; (c) (i) DIC, HOBT, MeCN,
(ii) N-acetylimidazole, DCM; (d) 2% TCA, DCM; (e) 8, tetrazole, MeCN; (f) Ac2O, 2,6-lutidine, N-methylimidazole; (g) I2, 2,6-lutidine, dioxane;
(h) NH3, H2O; (i) Pd/C, H2.
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natural D-alanine substituents was capable of inducing pro-
inflammatory cytokines in human whole blood to a similar
extent as the isolated material. In a human whole blood
cytokine response assay the synthetic material and the isolated
LTA stimulated the production of IL-1b, IL-6, IL-8, IL-10 and
TNF-a to a similar extent.37 The L-alanine bearing fragment was
Scheme 3 Fukase’s Streptococcus pyogenes LTA synthesis. Reagents and conditions: (a) (i) 13, tetrazole, DCM, MeCN, (ii)m-CPBA, 89%; (b) TBAF, THF,
99%; (c) bis(N,N-diisopropylamino)-O-benzyl-phosphoramidite, tetrazole, DCE, MeCN, 84%; (d) DDQ, H2O, DCM, 82%; (e) (i) 16, tetrazole, DCM, MeCN,
(ii) m-CPBA; (f) TBAF, THF, 88%; (g) bis(N,N-diisopropylamino)-O-benzyl-phosphoramidite, tetrazole, DCE, MeCN; (h) (i) tetrazole, DCM, MeCN,
(ii) m-CPBA; (i) Pd(0), H2, THF, MeOH, 48%.
Scheme 4 Schmidt’s Staphylococcus aeureus LTA synthesis. Reagents and conditions: (a) (i) 23 or 24, tetrazole, DCM, (ii) tBuO2H; (b) TBAF;
(c) (i) tetrazole, DCM, (ii) tBuO2H, 75%; (d) CAN, MeCN/toluene/H2O, 67%; (e) PyBOP, N-methylimidazole, Z-protected alanine, DCM; (f) Pd(OH)2-C, H2,
DCM/MeOH/H2O, 28: 33% over 2 steps, 29: 25% over 2 steps.
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100 times less active than the LTA fragment featuring the
naturally configured D-alanine residues. Deacylated, isolated
LTA (without lipid anchor or alanine residues) displayed no
immunostimulatory activity38 and was incapable of blocking
the activity of native LTA, indicating that it had lost its affinity
for its cellular binding partner. The lipid anchor alone showed
weak immunostimulatory activity. Combined, these results
show that for optimal innate immune stimulatory activity LTA
fragments should bear both the lipid anchor and a number of
D-alanine residues.
Subsequently, the Schmidt laboratory explored, through
the chemical synthesis of a variety of LTA fragments, the
importance of all structural components for immunostimulatory
activity. A convergent approach was devised that made it possible
to prepare several constructs by minor alterations of the synthetic
route. In 2005, the syntheses of fragments 30 and 31 were
described (see Fig. 4).39 Whereas LTA 30 only lacked the gentio-
biosyl moiety, derivative 31 features more radical changes: both
gentiobiosyl and GlcNAc moieties were omitted and the
D-alanine esters were replaced by the more stable amide analogues
on the C-2 glycerol residues of opposed stereochemistry. The
eﬀects of these modifications on the immunostimulatory pro-
perties were minimal, showing that the gentiobiosyl and GlcNAc
were not necessary for cytokine (IL-8, TNF-a) production in
human whole blood. The presence of the alanylated glycerol
phosphate backbone proved more important. This finding was
confirmed by the synthesis and evaluation of TA derivatives 32a–e.
Fig. 4 Schmidt’s synthetic LTA derivatives based on Staphylococcus
aureus.
Scheme 5 Schmidt’s Streptococcus species DSM 8747 LTA synthesis. Reagents and conditions: (a) TMSOTf, DCM, 89%; (b) NaOMe, MeOH; then BnBr,
NaH, DMF, 96%; (c) p-TsOH, DCM/MeCN, ethylene glycol, 76%; (d) DCM, DMAP, DCC, quant; (e) Pd/C, H2, TFA, EtOAc/MeOH, 90%; (f) TBDMSCl, DMAP,
Et3N, DCM, 63%; (g) BnBr, NaH, DMF, 90%; (h) TBAF, DCM, 76%; (i) BnOP(Ni-Pr2)2, diisopropanylammonium tetrazolide, 81%; (j) GTA pentamer, tetrazole,
DCM, then t-BuOOH, 90%; (k) CAN, MeCN, toluene, H2O, 85%; (l) N-methylimidazole, Cbz-D-alanine triethylammonium salt, PyBOP, DCM, 74%;
(m) Pd(OH)2, H2, DCM/MeOH/H2O (7 : 3 : 2), 28%.
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These compounds consist of the complete gentiobiosyl diacyl
glycerol moiety connected to an oligoglycerol phosphate backbone
ranging in length between two (32a) and six residues (32e)
and containing between one and five alanine modifications
(Fig. 4).40,41 Biological evaluation showed that a minimum of
two alanylated glycerol phosphates in the construct is required
for significant activity (10-fold increase of cytokine induction
compared to one alanylated residue). The gentiobiosyl diacyl
glycerol anchor (structure not shown) alone did not induce
any immune response. The role of TLR2 in the induction of
pro-inflammatory cytokines was investigated using peritoneal
macrophages from wild type and TLR2 knock out mice. Stimu-
lation of these cells by isolated LTA and LTAs 31 and 32e led to
the release of TNF-a and IL-8 by the wild type cells, but not
by the TLR –/– macrophages. Stimulation assays with TLR2
transfected HEK 293 cells corroborated the TLR2 dependent
activation by the LTAs. The group of Schmidt also reported the
synthesis of a construct that contained all the natural
substitutions and a second glycolipid moiety (structure 33,
Fig. 4).42 It was shown in a human whole blood cytokine release
assay that the titers of released IL-8 and TNF-a were a factor 10
higher compared to the monoglycolipid 28 (see Scheme 4). It
has been speculated that the altered presentation of the crucial
recognition elements, such as the D-alanyl esters, by this bis-
amphiphilic construct is responsible for the increase in activity.
The type I LTA from Streptococcus sp DSM 8747, a mutant
which is genetically related to Streptococcus pneumonia, consists
of a galactofuranoside diacyl glycerol glycolipid with the oligo-
glycerol phosphate backbone connected to the C-6 of the
galactofuranose residue. The backbone is substituted for about
30% at the glycerol C-2 position with D-alanine esters.43 In
2010, Schmidt and coworkers reported on the synthesis of a
fragment of this LTA.44 The b-galactofuranoside diacylglycerol
phosphoramidite 40 was constructed via the imidate glycosyla-
tion procedure using anchimeric assistance of a temporary
20-benzoyl ester, followed by several consecutive (protecting
Scheme 6 Pedersen’s Streptococcus pneumoniae LTA synthesis. Reagents and conditions: (a) (i) tetrazole, MeCN (ii) tBuOOH, Me2NH, EtOH, 68%;
(b) Pd(OH)2/C, H2, THF, H2O.
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group) manipulations (see Scheme 5). Block coupling of the
previously reported PMB-protected pentamer en route to 25 and
glycolipid phosphoramidite 40 using tetrazole followed by
oxidation yielded the fully protected intermediate in 90%. At
this stage the PMB ethers were selectively cleaved (85% yield)
and the resulting tetraol was decorated with alanyl moieties
using Cbz-D-alanine and PyBOP (74% yield). Global deprotec-
tion of the fully protected 43 (containing four alanine esters)
followed by purification resulted in the target LTA fragment 44
provided with roughly two alanine esters. It is unclear why
the alanine esters in this particular molecule were prone to
hydrolysis, as this phenomenon was not observed in similar
syntheses reported earlier by the group of Schmidt.35,39,40,42
Unfortunately, no immunological evaluation of the synthesized
LTA molecule has been reported to date.
The most impressive synthetic achievement in the TA
arena is undoubtedly the successful assembly of the complex
Streptococcus pneumoniae type IV LTA.45 This synthesis is
summarized in Scheme 6 and is based on the block coupling
of ribitol tetrasaccharide 54 and trisaccharide lipid anchor 55.
The tetrasaccharide unit 54 was synthesized by a series of
glycosylations, starting with the a-selective coupling of 46 and
47, followed by the acetonitrile mediated b-selective coupling of
the deacetylated disaccharide to tetrabenzyl donor 45. Another
acetonitrile mediated coupling between 48 and 49 yielded the
ribitol coupled galactosazide, which could be coupled to the
synthesized trisaccharide. Desilylation followed by introduction
of the phosphocholine residues furnished the ribitol tetra-
saccharide 54. Trisaccharide lipid anchor phosphoramidite 55
was synthesized by sequentially coupling 52, 51, and 50 to
Scheme 7 Seeberger’s Clostridium diﬃcile TA synthesis. Reagents and conditions: (a) 60, TMSOTf, DCM, Et2O, 20 1C to 10 1C, 81% (a :b = 9 : 1);
(b) DDQ, DCM, phosphate buﬀer, pH = 7.2, 0 1C to rt, 80%; (c) 61, TMSOTf, DCM, Et2O, 20 1C to 10 1C, 69% (a : b = 8 : 1); (d) AcSH, pyridine, 67%;
(e) Ir(COD)(Ph2MeP)2, THF; (f) N2H4 hydrate, AcOH, pyridine, DCM, 78% over 2 steps; (g) 2-cyanoethyl bis(N,N-diisopropylamino)phosphoramidite,
tetrazole, diisopropylamine, DCM, MeCN, 82%; (h) (i) 67 5-(ethylthio)tetrazole, MeCN, (ii) I2, H2O, THF, 98%; (i) (i) 68, 5-(ethylthio)tetrazole, MeCN, (ii) I2, H2O,
THF, 78%; (j) NEt3; (k) H2 (4 bar), Pd/C, H2O, AcOH; (l) di-N-succinimidyl adipate, NEt3, DMSO; (m) CRM197, 100 mM sodium phosphate, pH 7.4.
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glycerol residue 53. The crucial coupling between 54 and 55
yielded fragment 56 in 68% yield, showcasing the eﬀectiveness
of phosphoramidite chemistry. Compound 56 was deprotected
by hydrogenolysis over Pd(OH)2 in THF/H2O to provide target
compound 57 after hydrophobic interaction chromatography
(HIC). Unfortunately, no yield was reported for the final
deprotection step. The trisaccharide lipid anchor and the
tetrasaccharide ribitol were also deprotected to give fragments
59 and 58 for immunological evaluation. Preliminary immuno-
logical evaluation indicated that the compound, as well as the
trisaccharide lipid anchor lacking the tetrasaccharide ribitol
phosphate part, are capable of stimulating the production of
IL-8 in a human whole blood assay and an assay using human
mononuclear cells (MNCs). Using TLR2 and TLR4/MD2/CD14
transfected HEK 293 cells the intermediacy for these PRRs
in immunestimulation was ruled out. Binding studies of the
synthetic fragments with L-ficolin, and its fibrinogen recogni-
tion domain (FBG) indicated that compounds 57 and 58 could
be recognized by this soluble lectin from the complement
system.46 The interaction of the synthetic LTA and the ficolin
receptor triggers the activation of the lectin complement path-
way of the innate immune system. The binding of the FBG
domain with the TA fragments was further investigated in
competitive binding studies in which fragment 57 competed
with monosaccharides (mannose, glucose, N-acetyl galactosamine)
and phosphocholine for FBG binding. These studies indicated
that the GalNAc and phosphocholine residues are important
structural features for interaction of the S. pneumonia LTA
with L-ficolin.
Recently, two reports have described the assembly of
Clostridium diﬃcile TA fragments. This LTA has an ‘‘uncommon’’
structure as the diglucosylphosphate repeating units are not
connected through the anomeric center of the reducing end
glucosyl moiety, but through the C-6–OH of this residue. The
anomeric center of this glucosyl moiety is decorated with a
glycerate moiety. Deviating from the classical DNA chemistry,
that employs the acid labile dimethoxytrityl group for temporary
protection, the group of Seeberger reported an enol ether based
assembly strategy as shown in Scheme 7.47 The key building block
68 was synthesized starting with two sequential glycosylations on
glycerate 60 using trichloroimidates 63 and 61, giving diglycosyl-
glycerate 66. The azides on this disaccharide were converted into
acetamides and the levulinoyl group was removed to provide the
primary alcohol. Subsequent allyl isomerization yielded key enol
ether 67, which was transformed into phosphoramidite building
block 68. The assembly sequence of dimer repeat 70 started with
attachment of the spacer to alcohol 67. To this end phosphor-
amidite 62 was activated with 5-(ethylthio)tetrazole (ETT) and the
intermediate phosphite was oxidized with I2 in water. These
conditions also cleaved the enol ether to yield spacer equipped
monomer 69 in 98% yield. Subsequent elongation using phos-
phoramidite 68 proceeded in 78% yield and furnished protected
dimeric fragment 70. Deprotection of monomer 69 and dimer 70
furnished the C. difficile TA fragments that were analyzed for their
ability to bind antibodies in serum, taken from C. difficile-infected
patients using a microarray platform. Two out of three sera
contained IgG-antibodies against dimer 71 indicating that these
LTA fragments could be used as antigens in future vaccine
Scheme 8 Hogendorf’s Clostridium diﬃcile LTA synthesis. Reagents and conditions: (a) 60, TMSOTf, Et2O, 35 1C to 0 1C, 88%; (b) HFpyridine, THF,
98%; (c) 74, TMSOTf, Et2O, 35 1C to 0 1C, 60% (a : b = 15 : 1); (d) AcSH, pyridine, 68%; (e) HFpyridine, THF, 95%; (f) DMTr-Cl, pyridine, 91%; (g) DBU, DCM,
94%; (h) 2-cyanoethyl bis(N,N-diisopropylamino)phosphoramidite, tetrazole, diisopropylamine, DCM, 84%; (i) (i) 80, DCI, MeCN, (ii) I2, H2O, pyridine, THF,
(iii) DCA, TES-H, DCM, 82: 62%, 83: 74%, 84: 66%, 85: 56%, 86: 42%; (j) DBU, DCM, 76–97%; (k) Pd black, H2, THF, H2O, AcOH.
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modalities. To generate a conjugate vaccine, TA fragment 72 was
coupled to CRM197, a commonly used (licensed) carrier protein,
through an adipic acid linker.48 This vaccine modality (73) was
combined with two different adjuvants, alum and complete
Freund’s adjuvant. It was shown that the stand-alone conjugate
was highly immunogenic, indicating that the conjugate was
endowed with intrinsic adjuvant activity. However, the conju-
gate was not able to stimulate bone marrow dendritic cells
in vitro. The conjugate adsorbed onto alum provided the most
robust IgG response of the three vaccine formulations and this
construct was used in a mouse model. It was shown to offer
protection against C. difficile as revealed by diminished
C. difficile fecal levels in vaccinated mice with respect to
no-treated or CRM-treated mice.
Hogendorf et al. reported the synthesis of a set of C. diﬃcile
LTA fragments, diﬀering in the number of repeating units (1–5)
and containing the C. difficile trisaccharide glycolipid anchor
(Scheme 8).49 This synthesis was based on the use of the ‘classic’
DMTr-temporary protecting group. The key DMTr-phophoramidite
building block 80 was assembled using glucosazide synthons 74
and 75. First, benzylglycerate 60 was glycosylated in a stereo-
selective manner with donor 75 to give 76. Desilylation and
ensuing elongation with building block 74 then gave diglycosyl-
glycerate 78. The azides in this molecule were transformed into
acetamide groups and the primary TBDPS group was changed
into a DMTr-ether. Fmoc removal and phosphitylation gave
central building block 80. Anchor 81 was coupled to this
phosphoramidite, and subsequent oxidation and DMTr cleavage
yielded lipid-decorated monomer 82 in 62% yield over 3 steps.
Repetition of this sequence using phosphoramidite 80 yielded the
di-, tri-, tetra- and pentamers (83, 84, 85 and 86 respectively).
Deprotection followed by hydrophobic interaction chromato-
graphy gave the five C. difficile LTA fragments (87–91), which
were tested on their ability to stimulate the production of
pro-inflammatory cytokines by human mononuclear cells and in
a whole blood assay. However, no significant immunostimulatory
effect was observed.
Enterococcus faecalis and E. faecium are normally harmless
commensal bacteria inhabiting the gastrointestinal tract, but
they are also the causative agents of sepsis, endocarditis, wound
infections and urinary tract infections.50 They are amongst the
most prevalent nosocomial infectious agents and especially
multi-drug resistant enterococci pose a great problem. The
LTA of E. faecalis and feacium belongs to the class of type I
LTAs. The poly(glycerol phosphate) chain of these bacteria can
be decorated with either D-alanine residues or carbohydrate
appendages. E. faecalis LTA can carry kojibiosyl groups51 and
E. faecium has a-D-glucopyranosyl substituents.52 Our group
Scheme 9 Hogendorf’s Enterococcus faecalis TA synthesis. Reagents and conditions: (a) (i) 94, Tf2O, Ph2SO, TTBP, DCM, (a :b = 6 : 1), (ii) Na2CO3,
MeOH, 46%; (b) 93, Tf2O, Ph2SO, TTBP, DCM, 82%; (c) (i) Ir(COD)(Ph2MeP)2, THF, (ii) I2, aq. NaHCO3, 67%; (d) DMTr-Cl, Et3N, DCM, 98%; (e) TBAF, THF,
91%; (f) 2-cyanoethyl N,N-diisopropylchlorophosphoramidite, DIPEA, DCM, 72%; (g) (i) 102, 100, or 103, DCI, MeCN, (ii) I2, THF, H2O, pyridine, (iii) DCA,
TES-H, DCM or pyridinium p-toluenesulphonate, MeOH, DCM, 15% over 17 steps; (h) NH3, H2O, dioxane, 100%; (i) Pd black, H2, H2O, dioxane, 76%.
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developed several synthetic strategies to assemble a variety of
these enterococcal LTA fragments. Initially solution phase
chemistry was explored to generate a kojibiosyl functionalized
glycerol phosphate hexamer as depicted in Scheme 9. The
kojibiosyl synthon was synthesized using benzylidene protected
glucose donors to allow for stereoselective construction of the
a-glycosidic linkages. Using kojibiosyl glycerol phosphoramidite
100 and glycerol phosphoramidite 102, a hexamer was synthe-
sized starting from dibenzylglycerol 101. Aminohexanol phos-
phoramidite 103 was coupled to the decorated hexamer to yield
fully protected 104, which could be deprotected to yield spacer
functionalized E. faecalis TA hexamer 105.
Scheme 10 TA-synthesis using a Pse-based fluorous linker (A), Spirilliplanes yamanashiensis-TA synthesis (B), TA-synthesis using a succinate based
fluorous linker (C). Reagents and conditions: (a) (i) phosphoramidite, DCI, MeCN, (ii) I2, H2O, pyridine, THF, (iii) DCA, TES-H, DCM, towards 113: pyridinium
p-toluene sulphonate, MeOH, (iv) F-SPE, 71–99% over 4 steps; (b) conc. NH4OH, 40 1C; (c) Pd black, H2, H2O, AcOH, 76–98% over 2 steps; (d) succinic
anhydride, Et3N, DCM, 96%; (e) 2-cyanoethyl N,N-diisopropylchlorophosphoramidite, Et3N, DCM, 74%; (f) (i) 123, BOP, DIPEA, DMF, DCM, (ii) DCA,
TES-H, DCM, (iii) F-SPE, 90% over 3 steps.
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To streamline the assembly of TA fragments, a light-fluorous
phase synthesis strategy was developed. In this approach a
C8F17 fluorous support was used that allowed for the rapid
purification of the growing oligomers using fluorous solid
phase extraction (F-SPE). Building on the fluorous-propylsulfonyl-
ethoxycarbonyl (FPse) group, introduced by Ali et al.,53 a set of
LTA-oligomers was assembled54 (Scheme 10A). Using glycerol
phosphoramidite 102 in twelve consecutive coupling-oxidation-
DMTr cleavage reaction sequences, dodecamer 112 was eﬀectively
generated in 25% overall yield. The intermediate pentamer 111
could also be coupled to phosphoramidites 108, 109 or 110 and
spacer phosphoramidite 103 to yield fluorous supported 113, 114,
and 115 respectively. Subsequent deprotection yielded glucose,
N-acetyl glucosamine and glucosamine decorated hexamers 116,
117 and 118. To further explore the scope of this method, the
more complex TA from Spirilliplanes yamanashiensis was targeted
(Scheme 10B). Building block 119 was synthesized and coupled to
fluorous support 107 to end up, after six elongation cycles with
large hexamer 120 (4.7 kDa), which could be eﬀectively purified
using the C8F17 tail and F-SPE. Final deprotection yielded
TA-fragment 121.
The fluorous-propylsulfonylethoxycarbonyl (FPse) linker system
delivers TA fragments with a terminal phosphate monoester.
Because immunological evaluation of these LTA fragments
showed that the terminal phosphate group was detrimental
for the recognition of the fragments by anti-LTA antibodies,
another fluorous linker system was developed that delivers
TA fragments with a terminal alcohol group55 (Scheme 10C).
To this end fluorous amine 125 was condensed with succinate
equipped building block 123 giving fluorous synthon 126.
Applying the above described F-SPE-strategy, using perbenzylated
building block 124, hexamers 127 and 128 were synthesized.
Deprotection using concentrated ammonia cleaved the fluorous
succinate ester, releasing the hexamers with a terminal alcohol.
Hydrogenolysis then furnished hexamers 129 and 130.
Almost 25 years after the first automated solid phase TA
synthesis, this methodology was revisited for the generation of
a small set of TA fragments.56 Employing classical automated
DNA synthesis, the aforementioned building blocks 102, 124
and 103 were used to generate the set of TAs depicted in
Scheme 11. To this end, aminopropyl functionalized controlled
pore glass (CPG) was loaded with succinate functionalized
glycerol building block 132 or 123. The DMTr protecting group
was cleaved using 3% DCA in toluene and the released alcohols
were coupled with phosphoramidite 102 using 5-BTT as activator
to yield the phosphite intermediates, which were oxidized to
the corresponding phosphotriesters using I2 in pyridine. The
remaining unreacted alcohols were capped using acetic anhydride
and 2,6-lutidine. After repetitive coupling-oxidation-capping-
deprotection cycles spacer phosphoramidite 103 was coupled.
The products were cleaved from the resin under basic condi-
tions and purified by HPLC. Finally, hydrogenolysis yielded a
series of glycerol phosphate oligomers equipped with an amino-
hexanol spacer, varying in length from 6 to 20 glycerol phosphate
repeating units and incorporating glycoside residues at diﬀerent
positions on the backbone. The set of TAs was evaluated for their
ability to bind to opsonophagocytic antibodies, raised against
E. faecalis LTA, in an opsonophagocytic killing inhibition assay
(OPIA). It was observed that longer fragments showed increased
inhibition of the antibodies and especially the glycosylated
fragments 141 and 129 were found to be potent inhibitors. Of
note, the kojibiosyl functionalized TA fragment 105 proved to be
a relatively weak inhibitor for opsonophagocytic killing. Along
with the most potent inhibitor, hexamer 129, 105 was used to
generate a conjugate vaccine by coupling to BSA as a carrier
protein57 (Scheme 12). To this end TA-fragments 105 and 129
were equipped with a maleimide handle and linked to thiol-
functionalized BSA to deliver conjugates with approximately
20 TA fragments per BSA carrier. Immunization of rabbits with
the BSA conjugate of 129 provided serum containing opsono-
phagocytic antibodies able to mediate killing of clinical
E. faecalis strains. Notably, also E. faecium and S. aureus strains
were killed by the serum. In a passive immunization experiment
the serum was shown to oﬀer protection in a Rat endocarditis
model. The fragments have not yet been evaluated for their
innate immune system stimulating activity.
Snapper and co-workers also reported an approach to generate
an anti-staphylococcal vaccine based on synthetic poly(glycerol
phosphate).58 They applied a synthetic strategy that involves
benzoyl protected glycerol phosphoramidite 153 (Scheme 13).
Scheme 11 Automated solid phase TA synthesis. Reagents and conditions: (a) succinic anhydride, Et3N, DCM, 99%; (b) 132 or 123, DIC, MeCN;
(c) 3% DCA, toluene; (d) 102 or 124, 5-BTT, MeCN; (e) I2, pyridine, H2O, MeCN; (f) Ac2O, N-methylimidazole, 2,6-lutidine, MeCN; (g) 103, 5-BTT, MeCN;
(h) conc. NH4OH; (i) Pd black, H2, H2O, dioxane, AcOH.
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This building block was obtained by installing a levulinoyl
protecting group on solketal, removing the isopropylidene
group and protecting the primary alcohol with a DMTr ether.
Installation of a benzoyl group and removal of the temporary
Lev group with hydrazine then yielded alcohol 152, which was
equipped with a phosphoramidite functionality. This synthon
was used in an automated solid phase synthesis to generate a
decamer glycerol phosphate. Deprotection of the oligomer and
simultaneous cleavage from the solid support was achieved
under basic conditions. The product was purified by dialysis
and conjugated to tetanus toxoid using the 4-formylbenzaldehyde/
6-hydrazinonicotinamide conjugation method. Little experi-
mental details and no analytical data were provided to assess
the quality of the generated material. Given the propensity of
acyl groups to migrate from the secondary alcohol to the
primary one in glycerol substrates and the minimal purification
procedure, the identity of decamer 154 may be questionable.
The immunological evaluation of the conjugate revealed that
the vaccine cannot trigger an innate immune response, as
exposure of peritoneal cells to the conjugate did not lead to
significant IL-6 production. To provide an eﬀective vaccine, the
conjugate was adsorbed onto alum and combined with the
CpG-ODN adjuvant. This vaccine formulation was capable
of eliciting an immune response, as judge from a significant
boost in anti-poly(glycerol phosphate) IgG levels. The serum
raised with the vaccine was further characterized in an opso-
nophagocytic killing assay and shown to be capable of mediat-
ing S. aureus killing in vitro. Finally, the vaccine was evaluated
in a mouse bacteremia model, where it was shown to oﬀer
protection against infection by S. aureus.
In comparison to the amount of LTA syntheses reported to
date, relatively little eﬀort has been devoted to the synthesis
Scheme 13 Snapper’s anti-staphylococcal vaccine synthesis. Reagents and conditions: (a) levulinic acid; (b) 75% AcOH, H2O; (c) DMTr-Cl;
(d) benzoylchloride; (e) N2H4H2O, AcOH, pyridine; (f) 2-cyanoethyl N,N-diisopropylchlorophosphoramidite; (g) 4FB-OSu; (h) PBS, aniline.
Scheme 12 Generation of a glycerol phosphate conjugate vaccine. Reagents and conditions: (a) N-succinimidyl-3-maleimidopropionate, aq. NaHCO3,
143: 86%, 144: 67%; (b) (i) N-succinimidyl-3-thio-propionatehomodisulfide, PBS (pH = 8.0), DMF, (ii) dithiothreitol; (c) 143 or 144, PBS (pH = 7.2).
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Scheme 14 Pozsgay’s ribitolphosphate–BSA conjugate synthesis. Reagents and conditions: (a) (i) 159, tetrazole, MeCN, (ii) I2, pyridine, THF, H2O;
(b) AcOH, H2O, DCM; (c) conc. NH4OH, MeOH, 50 1C; (d) Pd/C, H2, t-BuOH, H2O; (e) 5-ketohexanoic anhydride, Et3N, MeOH, H2O; (f) aminooxy-BSA,
PBS (pH = 7.4), EDTA, glycerol.
Scheme 15 Enterococcus faeciumWTA synthesis.Reagents and conditions: (a) TfOH, DCM, 0 1C, 58%; (b) NIS, THF/H2O; (c) CF3(QNPh)Cl, K2CO3, acetone, quant
over 2 steps; (d) 175 or 176, TfOH, MeCN/EtCN/DCM, 40 1C, 177: 90% 178: 80%; (e) PMe3, dioxane/H2O; (f) Ac2O, NEt3, DCM; (g) TBAF, THF; (h) DMTrCl, NEt3,
DCM; (i) (1) Ir(COD)(Ph2MeP)2, THF; (2) NaHCO3, I2, H2O/THF, 179: 28% over 5 steps, 180: 46% over 5 steps; (j) di-isopropylethylamine, N,N-di-isopropylamino-2-
cyanoethyl-chlorophosphite, DCM, 181: 85% 182: 62%; (k) DCI, 179 or 180, MeCN; (l) DCI, 181 or 182, MeCN; (m) CSO, MeCN; (n) 3% TCA, DCM, 183: 72%, 184:
80%, 185: 62%, 186: 64%, 187: 69%, 188: 67%; (o) NH3(conc), dioxane; (p) Pd(0), H2, AcOH, H2O, 189: 73%, 190: 57%, 191: 44%, 192: 45%, 193: 49%, 194: 56%.
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of WTA fragments. Pozsgay and co-workers described the
assembly of oligo(ribitol phosphates) to allow for their immuno-
logical evaluation59 (Scheme 14). Using 2,3,4-benzyl protected,
DMTr-equipped ribitol-1-phosphoramidite 159, the automated
solid phase synthesis of these oligomers was attempted. They
reported however that an ‘‘intractable’’ mixture was obtained
upon cleavage of the products from the resin. Therefore this
method was excluded from further investigations and a
solution phase approach was undertaken. In these syntheses,
mild aqueous acetic acid mediated cleavage conditions were
applied to remove the DMTr group, as it was thought that
the acidic conditions could jeopardize the phosphotriester
bonds. Building on CBz-protected aminoethanol spacer 160,
up to 12 ribitol phosphate repeating units were installed.
The 8-mer and 12-mer were deprotected and conjugated to
BSA, yielding the two oligo(ribitol-1-phosphate) conjugates.
So far no immunological evaluation of these compounds has
been reported.
Recently we described the synthesis of various WTA structures
of E. faecium.60 The E. faecium TA is built up from -6-(GalNAc-a(1–
3)-GalNAc-b(1–2)-GroP)- repeating units and because the stereo-
chemistry of the glycerol moiety had not been established,
fragments with both sn-1 and sn-3 glycerol phosphates were
assembled. Key digalactosyl glycerol phosphoramidites 181 and
182, which were used for the assembly of mono- di- and trimers
183–188 were assembled as depicted in Scheme 15. For the
construction of both the b-galactosamine and a-galactosamine
linkage it was decided to use galactosazide synthons, allowing
for a more straightforward protecting group strategy. Building
blocks 171 and 172 were synthesized in several steps from
protected galactal 170 and they were subsequently reacted in a
stereoselective fashion, using triflic acid in DCM, providing
digalactosazide 173 as a single diastereoisomer. After hydrolysis
and introduction of a trifluoroimidate leaving group, the
acetonitrile-mediated glycosylation with either stereoisomer
of the semi-protected glycerol acceptor (175 and 176) yielded
the targeted glycerol disaccharides 177 and 178 in high yield
and excellent stereochemistry. Several protecting group mani-
pulations were executed to yield alcohols 179 and 180, which
could be phosphitylated to provide phosphoramidites 181
and 182. Assembly of the oligomeric fragments commenced
with the condensation, oxidation and detritylation of spacer
phosphoramidite 103 and either 179 or 180, yielding spacer
equipped monomers 183 and 184. Repetition of the aforemen-
tioned coupling cycle on 183 and 184 using phosphoramidites
181 and 182 provided di- and trimers 185–188. Deprotection of
all synthesized fragments using palladium catalyzed hydro-
genolysis gave the deprotected fragments (189–194), the NMR
spectra of which were compared with the NMR spectrum
obtained using a sample of isolated WTA. This provided
evidence for the absolute stereochemistry of the E. faecium
WTA glycerol phosphate indicating it to be sn-glycerol-3-
phosphate. This conclusion is corroborated by the fact that
the biosynthesis of WTAs generally uses CDP-sn-3 glycerol
synthons (vide supra). The immunological evaluation of the
fragments is currently ongoing.
Conclusion
Because of their biological relevance, the fact that they often
cannot be isolated in suﬃcient purity from natural sources and
their challenging structures, teichoic acids have been attractive
targets for organic synthesis for over 35 years now. Developments
in synthetic carbohydrate chemistry and nucleotide chemistry
have led to increasingly sophisticated TA syntheses. The advent
of phosphoramidite chemistry, a major step forward in the
construction of phosphotriester linkages, has enabled the assembly
of highly complex TAs as it allows the union of large and complex
TA fragments in a very reliable and eﬃcient manner. Further
progress in synthetic chemistry, including the development of
reliable and stereoselective glycosylation chemistry, and automated
solid-phase methods will allow more eﬃcient TA syntheses and the
generation of TA libraries.
Synthetic TAs have been instrumental in unraveling their
mode of action in immunology. By the hand of synthetic
Staphylococcus aureus LTA molecules the active principle of this
biopolymer has been elucidated and the involvement of TLR2
in the activation of the immune system by this TA confirmed.
For other TAs however the involvement of this PRR in immune
activation remains to be established. Given the wide structural
variety of TAs is, diﬀerent biological binding partners are likely
involved. Carbohydrate binding lectins of the complement
system have already been implied to be key interaction partners
and the generation of libraries of TAs will allow for the estab-
lishment of detailed structure–activity relationships in the near
future. Synthetic TAs of different bacteria have been probed for
their use as synthetic antigens in novel vaccine formulations.
Initial results with model vaccines against E. faecalis, S. aureus
and C. difficile are promising and it is not unlikely that TAs of
other Gram-positives will be used for similar purposes. These
synthetic antigens will also prove to be valuable tools in
unraveling the molecular details behind their mode of action,
in terms of antigen uptake, processing and presentation.
The availability of well-defined and functionalized TA fragments
will also open up avenues to explore the biosynthesis of these
important cell wall components providing leads for the develop-
ment of novel antibiotic regimes that interfere with the assembly of
these vital bacterial biopolymers.
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